In our public policy analyses, we leverage insights and data sources from our health economics and outcomes research, epidemiology, market access and public and commercial payer policies and practices. The results of our work have influenced public debate, referenda, health care industry forums, and innovative manufacturers’ business decisions, and have been published in white papers, testimony, and prominent health policy journals. Our public policy work is high profile, ranging from the effects of legislative and regulatory provisions on companies, to anticipated biosimilar or generic entry, to the evolving drug development pipeline. We have provided economic impact assessments and studies with respect to a variety of public policy matters. Drawing on analytical techniques from economics, statistical modelling, and health economics and outcomes research, our consultants have evaluated the costs and benefits of alternative policies affecting drug market access and commercialisation.
Our services include: